Singapore, Oct. 8 -- Taiwan based Lotus Pharmaceutical, a leading global pharmaceutical company, has entered into a License and Supply Agreement with Europe's Adalvo to commercialise its Semaglutide injection for obesity (Wegovy(R) generic) and diabetes (Ozempic(R) 2mg generic) in multiple Asian markets, including South Korea, Taiwan and a number of Southeast Asian countries.

In particular, Lotus will hold the exclusive rights to the Wegovy generic to be commercialised in South Korea, Taiwan, Thailand, Singapore and Vietnam. Lotus will initiate the registration processes in these markets with the aim to launch as first generic in their corresponding markets.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is one of the ...